Evidence map›Paper›PMID 27462776›Full record

ArticleOncotarget2016

MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma.

Xudong Zhang, Weiguo Ji, Ruixia Huang, Lifeng Li, Xinhua Wang, Ling Li, Xiaorui Fu, Zhenchang Sun, Zhaoming Li, Qingjiang Chen and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xudong ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Weiguo JiDepartment of Oncology, Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450008, China.
Ruixia HuangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Lifeng LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Xinhua WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Ling LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Xiaorui FuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Zhenchang SunDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Zhaoming LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Qingjiang ChenDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
Mingzhi ZhangDepartment of Oncology, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China.
First Affiliated Hospital of Zhengzhou University · CNHenan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer/T-cell lymphoma (NKTCL) is characterized by its highly aggressive nature and rapid progression. MicroRNAs (miRNAs) play key roles in the development of NKTCL. We utilized next-generation Solexa high-throughput sequencing to compare miRNA expression in the SNK-6 and YTS NKTCL cell lines with expression in normal NK cells. We found that 195 miRNAs were upregulated in the SNK-6 cells and 286 miRNAs were upregulated in the YTS cells. Based on those results, we selected six miRNAs, including miRNA-155, and confirmed their expression using real-time polymerase chain reaction. Expression of miRNA-155 was higher in SNK-6 and YKS cells than in normal NK cells. We next determined the levels of miRNA-155 in the serum of healthy individuals and NKTCL patients, and correlated its expression with clinical parameters and inflammatory factors detected using enzyme-linked immunoabsorbent assays. Levels of miRNA-155 were higher in NKTCL patients' serum than in serum from healthy individuals. miRNA-155 expression was higher in patients with stable or progressive disease (SD+PD) than in those with partial or complete remission (PR+CR). While further studies are needed to clarify the underlying molecular mechanisms, it appears miRNA-155 may be a molecular marker of NKTCL.

Indexed as

Biomarkers, TumorHumansLymphoma, Extranodal NK-T-CellMicroRNAsBiomarkers, TumorMicroRNAsMIRN155 microRNA, humanmiRNAmiRNA-155natural killer/T-cell lymphomaSolexa high-throughput sequencing

Identifiers

PMID27462776
PMCPMC5288223
OpenAlexW2477644871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.